ONCOLOGY

This treatment-induced damage could contribute to the emotional dysregulation in patients with brain tumours who undergo radiotherapy

HDAC8-specific inhibitors may limit BRAF-MEK inhibition.

High-dose lapatinib is tolerable when alternating with capecitabine.

By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.

More than half of patients with ROS1 fusion-positive NSCLC and brain metastases respond to entrectinib

Best outcomes with highest exposure, good presurgical T-cell function.

Reductions in mortality driven by lung cancer in men, breast cancer in women.

The newly identified genetic signature can classify non-WNT/SHH medulloblastoma patients into favourable- and high-risk groups.

Updated phase II data for the novel immunotherapeutic (SL-701) show “preliminarily promising survival curve” with good tolerability

Moderate-quality evidence supports doubled prophylactic benefit.

57% intracranial clinical benefit in phase 2 trial.

Overall, the incidence of cancer was 1.5 times higher in children who had received at least one CT scan five years previously.

The new review process will streamline FDA evaluation of other oncology drugs.

A NICE appraisal committee determined that it would be “unethical” not to offer the treatment to patients in the UK